OncoLens develops oncology-focused AI that extracts key insights from structured and unstructured clinical, molecular, and lab data to identify patients who may have missed treatment-defining diagnostics or therapies in real time. Its collaboration solutions help cancer centers coordinate next steps to ensure timely, multidisciplinary action. The company serves national cancer institutes, academic medical centers, and community-based integrated delivery networks, and also operates internationally after launching in the EMEA region in 2022. With a growing customer base, OncoLens launched the OncoLens Research Network to partner with life‑science commercial, real‑world evidence, and clinical development teams to bring trials and quality-improvement initiatives to its centers. For life‑science partners the company offers access to a diverse, community-focused network to address RWE, diversity and inclusion in trials, and to find patients with rare genomic alterations. The company is led by CEO Anju Mathew and recently raised capital to expand its development efforts. OncoLens provides an integration and collaboration platform to cancer centers that enables multidisciplinary cancer care across the continuum. Through a streamlined, secure HIPAA-compliant infrastructure it drives intra-enterprise, community, and network participation in multidisciplinary care planning, tracking, and delivery. Patients can collaborate on treatment plans, track quality for accreditation, and align to care pathways, while health systems can maximize clinical trial participation and referral streams. The company supports creation of centers of excellence that can be leveraged for patient care and provider education. It serves more than 200 cancer centers in the U.S. and has clients in the larger EMEA region. Led by CEO Anju Mathew, OncoLens intends to use the new funds to expand domestic and global footprint into rural communities and low- and middle-income countries to improve capacity, access, and diversity in research. The financial terms of the investment were not disclosed. OncoLens offers a collaborative, HIPAA-compliant tumor board and cancer treatment planning platform that aggregates patient-specific data across EMR, clinical, and genetics systems and provides decision support. Its software includes virtual tumor board technology, workflow automation, survivorship care planning, and clinical decision support to standardize care and improve efficiencies. The platform automatically identifies patient-specific clinical trials at a facility or affiliates and surfaces relevant NCCN/ASCO guidelines and the latest research to support care teams. OncoLens is used or being implemented across several National Cancer Institute-designated cancer centers and large U.S. healthcare delivery networks, and currently serves more than 8,000 cancer care providers. The company has received market recognition with studies showcased in professional journals and conferences. Management says the new funding will accelerate product development and market expansion as it builds on its position in tumor board and treatment-planning software. OncoLens develops tumor board and cancer treatment planning software that consolidates clinical, radiological, and pathological data to streamline multidisciplinary case discussions. Its platform includes an intelligent workflow engine that automates accreditation and quality reporting, facilitates survivorship care planning, and supports more informed clinical decision-making. The company uses proprietary algorithms to reduce clinician workload by matching patients with relevant clinical trials and potential targeted therapies. OncoLens currently serves several large integrated delivery networks (IDNs) and hospitals across the U.S. Led by co-founder and CEO Anju Mathew, the company plans to expand its product capabilities and grow sales and marketing resources using new funding. The recent financing strengthens its position to scale adoption among health systems. OncoLens offers a Software-as-a-Service platform that enables diverse, multispecialty cancer care teams to collaborate on individual patient treatment plans. The platform provides cancer-specific clinical decision support, helps programs track and implement nationally approved quality metrics, and surfaces applicable clinical trials. It consolidates case data and workflows to streamline tumor board management and survivorship care planning, reducing the manual data-aggregation burden described in the article. OncoLens says its solution decreases a cancer center’s workload and saves resources by standardizing discussions and integrating multiple workflows. The company recently closed a $1.35 million seed round to fund strategic growth and product expansion. OncoLens is part of Georgia Tech’s ATDC Accelerate portfolio and has received industry recognitions, including an “Exceptional Research Award” from the Academy of Oncology Nurse Navigators.

Total raised

$27M

Funding rounds

5

Latest round

Series A

Latest activity

Oct 2024